It was reported yesterday that the US Food and Drug Administration (USFDA) has granted breakthrough therapy designation to United States-based Celgene's Pomalyst (pomalidomide) intended for the treatment of HIV.
The designation has been granted for the product to treat patients with HIV-positive Kaposi sarcoma who have earlier received systemic chemotherapy, in addition to patients with HIV-negative Kaposi's sarcoma.
Pomalyst is one of the firm's IMiD agents for the treatment of some blood cancers. It is a thalidomide analogue indicated, in combination with dexamethasone, to treat patients with multiple myeloma who have received at least two prior therapies including lenalidomide and proteasome inhibitor.
Blueprint Medicines reports EMA validation of avapritinib MAA for treatment of GIST
US FDA grants approval to Merck's Recarbrio
Sobi concludes CHF515m acquisition of emapalumab and related assets
PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema
Sun Pharma Launches Access Program for Patients Prescribed Xelpros in the US
US FDA grants priority review status to Novartis' crizanlizumab
Sosei reports FDA approval for APP13007 IND for first-in-human (FIH) clinical trial in the US